John M Corkery1, Peter Streete2, Hugh Claridge3, Christine Goodair3, Duccio Papanti1, Laura Orsolini1, Fabrizio Schifano1, Kanav Sikka1, Sophie Körber4, Amy Hendricks5. 1. Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, Department of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, UK. 2. Hampshire Scientific Service, Southsea, UK. 3. National Programme on Substance Abuse Deaths, Population Health Research Institute, St George's, University of London, London, UK. 4. Department of Pharmaceutical Science, University of Basel, Basel, Switzerland. 5. Retired Forensic Pathology Technician, Santa Clara County, CA, USA.
Abstract
BACKGROUND: Kratom (Mitragyna speciosa Korth) use has increased in Western countries, with a rising number of associated deaths. There is growing debate about the involvement of kratom in these events. AIMS: This study details the characteristics of such fatalities and provides a 'state-of-the-art' review. METHODS: UK cases were identified from mortality registers by searching with the terms 'kratom', 'mitragynine', etc. Databases and online media were searched using these terms and 'death', 'fatal*', 'overdose', 'poisoning', etc. to identify additional cases; details were obtained from relevant officials. Case characteristics were extracted into an Excel spreadsheet, and analysed employing descriptive statistics and thematic analysis. RESULTS: Typical case characteristics (n = 156): male (80%), mean age 32.3 years, White (100%), drug abuse history (95%); reasons for use included self-medication, recreation, relaxation, bodybuilding, and avoiding positive drug tests. Mitragynine alone was identified/implicated in 23% of cases. Poly substance use was common (87%), typically controlled/recreational drugs, therapeutic drugs, and alcohol. Death cause(s) included toxic effects of kratom ± other substances; underlying health issues. CONCLUSIONS: These findings add substantially to the knowledge base on kratom-associated deaths; these need systematic, accurate recording. Kratom's safety profile remains only partially understood; toxic and fatal levels require quantification.
BACKGROUND:Kratom (Mitragyna speciosa Korth) use has increased in Western countries, with a rising number of associated deaths. There is growing debate about the involvement of kratom in these events. AIMS: This study details the characteristics of such fatalities and provides a 'state-of-the-art' review. METHODS: UK cases were identified from mortality registers by searching with the terms 'kratom', 'mitragynine', etc. Databases and online media were searched using these terms and 'death', 'fatal*', 'overdose', 'poisoning', etc. to identify additional cases; details were obtained from relevant officials. Case characteristics were extracted into an Excel spreadsheet, and analysed employing descriptive statistics and thematic analysis. RESULTS: Typical case characteristics (n = 156): male (80%), mean age 32.3 years, White (100%), drug abuse history (95%); reasons for use included self-medication, recreation, relaxation, bodybuilding, and avoiding positive drug tests. Mitragynine alone was identified/implicated in 23% of cases. Poly substance use was common (87%), typically controlled/recreational drugs, therapeutic drugs, and alcohol. Death cause(s) included toxic effects of kratom ± other substances; underlying health issues. CONCLUSIONS: These findings add substantially to the knowledge base on kratom-associated deaths; these need systematic, accurate recording. Kratom's safety profile remains only partially understood; toxic and fatal levels require quantification.
Entities:
Keywords:
Mitragynine; cause of death; characteristics; kratom; toxicology
Authors: Laura Flores-Bocanegra; Huzefa A Raja; Tyler N Graf; Mario Augustinović; E Diane Wallace; Shabnam Hematian; Joshua J Kellogg; Daniel A Todd; Nadja B Cech; Nicholas H Oberlies Journal: J Nat Prod Date: 2020-06-29 Impact factor: 4.050
Authors: Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John M Corkery; Giovanni Martinotti; Daniel R Harris; Fabrizio Schifano Journal: Pharmaceuticals (Basel) Date: 2022-05-27
Authors: Mohammad Farris Iman Leong Bin Abdullah; Kok Leng Tan; Salbiah Mohd Isa; Nur Sabrina Yusoff; Nelson Jeng Yeou Chear; Darshan Singh Journal: PLoS One Date: 2020-06-11 Impact factor: 3.240
Authors: Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers Journal: Hum Psychopharmacol Date: 2021-07-26 Impact factor: 2.130